Analyst Update: BioScrip, ZIOPHARM Oncology, Cree

Analysts adjusted their ratings on BioScrip Inc (BIOS), ZIOPHARM Oncology Inc. (ZIOP), and Cree, Inc. (CREE)

Mar 10, 2015 at 12:07 PM
facebook twitter linkedin


Analysts are weighing in today on biotechnology firms BioScrip Inc (NASDAQ:BIOS) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), as well as LED specialist Cree, Inc. (NASDAQ:CREE). Here's a quick look at today's brokerage notes on BIOS, ZIOP, and CREE.

  • This morning, Dougherty & Company cut its price target on BIOS to $7.50 from $8 (while underscoring a "buy" rating), sending the shares to a five-year low of $3.65. At last check, BioScrip Inc has trimmed its deficit to 12.09% to linger at $3.79, bringing its year-to-date loss to 45.8%. Accordingly, put buying has ramped up in the options pits, as BIOS' 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 3.90 sits just 6 percentage points away from a pessimistic peak. What's more, BIOS' poor technical performance has earned it a spot on the short-sale restricted (SSR) list. Nearly 20% of the stock's available float is already sold short, which would take almost three weeks to cover, at average trading volumes.

  • Mizuho downgraded ZIOP to "neutral" from "buy," citing concerns about the stock's valuation. Today, the shares of ZIOPHARM Oncology Inc. are down 4.6% to hit $13.27. Looking back, however, ZIOP has been a technical juggernaut, with the shares up a staggering 161.7% year-to-date. Yesterday, though, the equity was placed (and remains) on the SSR list, after the shares plummeted more than 10% out of the gate (but ultimately resolved to the upside). Short interest accounts for over 27% of the stock's available float, which would take nearly 13 sessions to cover, at average trading volumes. Sentiment in the options pits is nearing a bearish climax, as ZIOP's 50-day ISE/CBOE/PHLX put/call volume ratio of 0.16 sits just 6 percentage points away the highest similar reading taken over the past year.

  • Last night, Canaccord Genuity raised its price target on CREE by $5 to $34, but underscored a "hold" rating. At last check, the shares of Cree, Inc. are bucking the broad-market trend lower -- up 0.1% to hit $38.84, contributing to a 20.5% year-to-date gain. As such, call activity is more popular than usual in the stock's options pits, as CREE's Schaeffer's put/call open interest ratio (SOIR) of 0.57 sits in the 32nd percentile of its annual range. Simply stated, short-term traders are more call-skewed than usual.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners